ResMed Inc.
252.86USD
-0.2000 (-0.08%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on RMD.
| In $M except per-share | Q4 FY26* | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,464 | 1,431 | 1,423 | 1,336 | 1,348 | 1,292 | 1,282 | 1,225 |
| Cost of Revenue | 602 | 540 | 544 | 515 | 528 | 525 | 531 | 507 |
| Gross Profit | 861 | 891 | 879 | 821 | 820 | 766 | 751 | 717 |
| Operating Income | 449 | 500 | 492 | 447 | 455 | 426 | 417 | 387 |
| Net Income | 383 | 399 | 393 | 349 | 380 | 365 | 345 | 311 |
| EPS (Diluted) | $2.64 | $2.74 | $2.68 | $2.37 | $2.58 | $2.48 | $2.34 | $2.11 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)